阿尔尼拉姆制药公司
ALNY
查看详细走势图
328.160USD
-3.080-0.93%
收盘 02/06, 16:00（美东）报价延迟15分钟
43.25B总市值
1010.56市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-0.93%
5天
-2.93%
1月
-19.25%
6月
-23.35%
今年开始到现在
-17.48%
1年
+17.94%
查看详细走势图
TradingKey 阿尔尼拉姆制药公司股票评分
单位: USD 更新时间: 2026-02-06操作建议
阿尔尼拉姆制药公司当前公司基本面数据相对健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在药品行业排名38/159位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价473.08。中期看，股价处于下降通道。近一个月，市场表现非常差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
阿尔尼拉姆制药公司评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
阿尔尼拉姆制药公司亮点
亮点风险
Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.
业绩高增长
公司营业收入稳步增长，连续3年增长116.72%
估值高估
公司最新PE估值1010.56，处于3年历史高位
机构减仓
最新机构持股132.38M股，环比减少0.01%
ETHSX持仓
明星投资者ETHSX持仓，最新持仓市值7.70K
活跃度增加
近期活跃度增加，过去20天平均换手率0.39
分析师目标
根据
30
位分析师
买入
评级
473.082
目标均价
+42.82%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
阿尔尼拉姆制药公司新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
阿尔尼拉姆制药公司简介
Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.
公司代码ALNY
公司阿尔尼拉姆制药公司
CEOGreenstreet (Yvonne L)
网址https://www.alnylam.com/
相关品种
